Meropenem in the treatment of febrile neutropenic children

J. Müller, M. Garami, T. Constantin, Marianne Schmidt, G. Fekete, Gábor Kovács

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The aim of this retrospective study was to evaluate the clinical effectiveness of meropenem in immunocompromised children. Between January 1998 and December 2002 in the hemato-oncological units of our hospital meropenem was used in 87 febrile events diagnosed in 55 patients, and 328 bacterial cultures were evaluated. Microorganisms were detected and identified in 64 of the 328 hemocultures; there was a predominance of gram-positive strains (67%). In 49.4% the infection was documented microbiologically. In 16 additional cases the infection was proven clinically and 32.2% of the episodes were considered to be fever of unknown origin. The success rate of the meropenem therapy-excluding the proven fungal or coagulase-negative Staphylococcus infections-was 72.9% and for the whole cohort 49.4%. The results demonstrate that meropenem is effective and well-tolerated when used for the treatment of neutropenic cancer children.

Original languageEnglish
Pages (from-to)277-284
Number of pages8
JournalPediatric Hematology and Oncology
Volume22
Issue number4
DOIs
Publication statusPublished - Jun 2005

Fingerprint

meropenem
Fever
Infection
Fever of Unknown Origin
Hospital Units
Coagulase
Therapeutics
Staphylococcus
Retrospective Studies

Keywords

  • Antibiotics
  • Febrile neutropenia
  • Immunosuppression
  • Infection
  • Meropenem

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Cancer Research

Cite this

Meropenem in the treatment of febrile neutropenic children. / Müller, J.; Garami, M.; Constantin, T.; Schmidt, Marianne; Fekete, G.; Kovács, Gábor.

In: Pediatric Hematology and Oncology, Vol. 22, No. 4, 06.2005, p. 277-284.

Research output: Contribution to journalArticle

@article{82aee38cf2824d2db03c028f5a34bc20,
title = "Meropenem in the treatment of febrile neutropenic children",
abstract = "The aim of this retrospective study was to evaluate the clinical effectiveness of meropenem in immunocompromised children. Between January 1998 and December 2002 in the hemato-oncological units of our hospital meropenem was used in 87 febrile events diagnosed in 55 patients, and 328 bacterial cultures were evaluated. Microorganisms were detected and identified in 64 of the 328 hemocultures; there was a predominance of gram-positive strains (67{\%}). In 49.4{\%} the infection was documented microbiologically. In 16 additional cases the infection was proven clinically and 32.2{\%} of the episodes were considered to be fever of unknown origin. The success rate of the meropenem therapy-excluding the proven fungal or coagulase-negative Staphylococcus infections-was 72.9{\%} and for the whole cohort 49.4{\%}. The results demonstrate that meropenem is effective and well-tolerated when used for the treatment of neutropenic cancer children.",
keywords = "Antibiotics, Febrile neutropenia, Immunosuppression, Infection, Meropenem",
author = "J. M{\"u}ller and M. Garami and T. Constantin and Marianne Schmidt and G. Fekete and G{\'a}bor Kov{\'a}cs",
year = "2005",
month = "6",
doi = "10.1080/08880010590935167",
language = "English",
volume = "22",
pages = "277--284",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Meropenem in the treatment of febrile neutropenic children

AU - Müller, J.

AU - Garami, M.

AU - Constantin, T.

AU - Schmidt, Marianne

AU - Fekete, G.

AU - Kovács, Gábor

PY - 2005/6

Y1 - 2005/6

N2 - The aim of this retrospective study was to evaluate the clinical effectiveness of meropenem in immunocompromised children. Between January 1998 and December 2002 in the hemato-oncological units of our hospital meropenem was used in 87 febrile events diagnosed in 55 patients, and 328 bacterial cultures were evaluated. Microorganisms were detected and identified in 64 of the 328 hemocultures; there was a predominance of gram-positive strains (67%). In 49.4% the infection was documented microbiologically. In 16 additional cases the infection was proven clinically and 32.2% of the episodes were considered to be fever of unknown origin. The success rate of the meropenem therapy-excluding the proven fungal or coagulase-negative Staphylococcus infections-was 72.9% and for the whole cohort 49.4%. The results demonstrate that meropenem is effective and well-tolerated when used for the treatment of neutropenic cancer children.

AB - The aim of this retrospective study was to evaluate the clinical effectiveness of meropenem in immunocompromised children. Between January 1998 and December 2002 in the hemato-oncological units of our hospital meropenem was used in 87 febrile events diagnosed in 55 patients, and 328 bacterial cultures were evaluated. Microorganisms were detected and identified in 64 of the 328 hemocultures; there was a predominance of gram-positive strains (67%). In 49.4% the infection was documented microbiologically. In 16 additional cases the infection was proven clinically and 32.2% of the episodes were considered to be fever of unknown origin. The success rate of the meropenem therapy-excluding the proven fungal or coagulase-negative Staphylococcus infections-was 72.9% and for the whole cohort 49.4%. The results demonstrate that meropenem is effective and well-tolerated when used for the treatment of neutropenic cancer children.

KW - Antibiotics

KW - Febrile neutropenia

KW - Immunosuppression

KW - Infection

KW - Meropenem

UR - http://www.scopus.com/inward/record.url?scp=20044383582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044383582&partnerID=8YFLogxK

U2 - 10.1080/08880010590935167

DO - 10.1080/08880010590935167

M3 - Article

VL - 22

SP - 277

EP - 284

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 4

ER -